Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
SARS-CoV-2, the causative agent of COVID-191, recognizes host cells by attaching its receptor-binding domain (RBD) to the host receptor ACE2. Neutralizing antibodies that block RBD-ACE2 interaction have been a major focus for therapeutic development. The best sybody, MR3 bound to RBD with high affinity and showed high neutralization activity against SARS-CoV-2 pseudoviruses. And the divalent MR3 conjugated with the albumin-binding domain for prolonged half-life displayed highest potency and can protect mice from live SARS-CoV-2 challenge.